Metabolic Plasticity Is an Essential Requirement of Acquired Tyrosine Kinase Inhibitor Resistance in Chronic Myeloid Leukemia

Metabolic Plasticity Is an Essential Requirement of Acquired Tyrosine Kinase Inhibitor Resistance in Chronic Myeloid Leukemia

Tyrosine kinase inhibitors (TKIs) are currently the standard chemotherapeutic agents for the treatment of chronic myeloid leukemia (CML). However, due to TKI resistance acquisition in CML patients, identification of new vulnerabilities is urgently required for a sustained response to therapy. In thi...

Full description

Bibliographic Details
Main Authors: Miriam G. Contreras Mostazo, Nina Kurrle, Marta Casado, Dominik Fuhrmann, Islam Alshamleh, Björn Häupl, Paloma Martín-Sanz, Bernhard Brüne, Hubert Serve, Harald Schwalbe, Frank Schnütgen, Silvia Marin, Marta Cascante
Format: Article
Language:English
Published: MDPI AG 2020-11-01
Series:Cancers
Subjects:
tyrosine kinase inhibitors
chronic myeloid leukemia
metabolic reprogramming
proteomics
Online Access:https://www.mdpi.com/2072-6694/12/11/3443

Internet

https://www.mdpi.com/2072-6694/12/11/3443

Similar Items